ArticleBMC musculoskeletal disorders2025
Hybrid-J shape needle in ultrasound-guided looped thread carpal tunnel release: a cadaveric study on safety and efficacy.
Article in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundCarpal tunnel syndrome (CTS) is the most prevalent peripheral nerve entrapment disorder, often requiring surgical intervention. While Ultrasound-guided Looped Thread Carpal Tunnel Release (LTCTR) offers a minimally invasive alternative to carpal tunnel release, its implementation faces limitations due to insufficient specialized instruments. This cadaveric study assesses the Hybrid-J Shape Needle (HJSN), a blunt-tip, J-shaped device designed to improve safety in LTCTR procedures.
methodsTwenty fresh-frozen cadaveric specimens (40 wrists) were included. Ten junior surgeons were randomly assigned two cadavers, performing LTCTR with normal cannula needle (NCN) on one wrist of the same cadaver, followed by HJSN on the contralateral wrist. Intraoperative structural damage such as nerve, blood vessel and tendon were assessed by blinded observer and anatomist. Post-procedural dissection confirmed transverse carpal ligament (TCL) transection completeness. Surgeons evaluated usability, adoption intent, and likelihood of recommendation using 5-point Likert scales. Biomechanical testing assessed force thresholds required for tendon and nerve penetration. Statistical analysis included Mann-Whitney U-test, Student's t-test, and Chi-square tests.
resultsHJSN reduced operative time compared to NCN (25.10 ± 6.50 vs. 31.49 ± 6.36 min, p < 0.01) and achieved 100% complete TCL transection (20/20 vs. 16/20 for NCN, p = 0.035). NCN resulted in 3 median nerve (MN) injuries, 2 ulnar artery injuries, 2 superficial palmar arch (SPA) injuries, and 2 tendon injuries, whereas HJSN caused only 1 SPA injury (OR = 10.23, 95% CI: 1.12-93.34, p = 0.02). Biomechanical testing demonstrated HJSN required higher force to penetrate tendons (27.07 ± 2.43 N vs. 9.89 ± 2.53 N, p < 0.01) and nerves (25.75 ± 3.26 N vs. 10.72 ± 2.61 N, p < 0.01). Surgeons reported stronger preference for HJSN (3.60 ± 1.07 vs. 2.40 ± 1.07, p = 0.03) and recommendation (3.80 ± 1.23 vs. 2.20 ± 1.03, p < 0.01), though usability scores were comparable (4.10 ± 1.10 vs. 3.50 ± 1.18, p = 0.22).
conclusionHJSN's unique blunt-tip and J-shaped design improves LTCTR safety by reducing iatrogenic injuries and ensuring complete TCL release. Its biomechanical superiority and surgeon preference support clinical translation, especially for trainees. While cadaveric data are encouraging, clinical trials are needed to confirm efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.